The antiviral medication Paxlovid, developed to treat COVID-19 infections, has been introduced in Turku both in outpatient care and in hospital wards. Paxlovid is only administered to nationally established target groups. The drug is free for patients, and the decision on Paxlovid treatment is always made by a physician.

Contact us

If you belong to a risk group and have recently tested positive for COVID-19, please contact:

  • Turku coronavirus helpline 02 266 2714, Mon–Thu at 8:00–15:00 and Fri at 8:00–13:00
  • On weekends and holidays, call the Tyks Acute helpline, tel. 02 313 8800.

Coronavirus testing

To get tested, you need a referral and an appointment.

  • You can get a referral either through the service or the coronavirus helpline, tel. 02 266 2714, Mon–Thu 8:00–15:00 and Fri 8:00–13:00.
  • Tykslab locations (

Read more: What to do if you suspect having caught the coronavirus infection

Paxlovid medication requires a careful assessment of the situation, and the decision to start treatment is made by a physician. The medication must be started as quickly as possible once the COVID-19 symptoms emerge and 5 days from the onset of symptoms at the latest.

The treatment may begin based on a positive result of a home test, which should be confirmed by a laboratory test as soon as possible. The target groups of Paxlovid treatment differ from the usual risk groups regarding COVID-19 infections. 

The medication is only available to persons belonging to specific target groups

Paxlovid treatment is available to patients in the following target groups who have tested positive for COVID-19 on an official PCR test:

A) Patients who have an illness or condition that is highly predisposing to severe coronavirus disease, regardless of the vaccinations received:

  • Organ or stem cell transplantation less than six months ago or ongoing use of strong anti-rejection drugs
  • Ongoing active cancer treatment 
  • Severe disorders of the immune system
  • Rituximab treatment within less than 6 months, or in cases of low levels of immunoglobulin after previous rituximab treatment

B) Patients who have an illness or condition that is highly predisposing to severe coronavirus disease, if the patient has not been vaccinated over 60 years old:

  • Severe chronic renal disease
  • Severe chronic pulmonary disease
  • Type 2 diabetes with medication (only the unvaccinated or those over the age of 60 who have been vaccinated fewer than four times)
  • Down syndrome

C) Patients who have an illness or condition that is predisposing to severe coronavirus disease, if the patient is over the age of 40 and unvaccinated:

  • Asthma requiring continuous medication
  • Severe heart disease
  • Neurological illness or condition that affects breathing
  • Immunosuppressive drug therapy for autoimmune disease
  • Severe chronic liver disease
  • Type 1 diabetes or adrenal insufficiency 
  • Severe or moderate sleep apnoea
  • Morbid obesity BMI>40 (treatment can be considered also for patients under the age of 40 if they have not been vaccinated)

D) Paxlovid can also be administered to patients over the age of 80 who live independently at home if they have received less than four vaccine doses. 
Especially in the case of elderly patients, the potential loss of drug efficacy due to possible adverse and combined effects of the drug must be considered carefully.


  • A previous COVID-19 infection is considered equivalent to one vaccine dose. 
  • Persons with only one vaccine dose are treated as unvaccinated